Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6644012 | 0.75 | HTR2C (0.40) | HTR2CNPC1RAB9ADRD2HTR2A | |
| SCHEMBL6642596 | 0.72 | HTT (0.49) | MEN1KMT2AJAK2JAK1TYK2 | |
| SCHEMBL30735496 | 0.71 | HTR2C (0.50) | HTR2CMEN1KMT2AADRB2SLC18A3 | |
| SCHEMBL6595004 | 0.71 | HTR2C (0.47) | HTR2CADRB2HTR1ASLC6A2SLC6A4 | |
| SCHEMBL6275687 | 0.71 | HTR2C (0.50) | HTR2CMEN1KMT2AADRB2SLC18A3 | |
| SCHEMBL6637094 | 0.70 | HTR2C (0.51) | HTR2CJAK2JAK1TYK2JAK3 | |
| SCHEMBL6639009 | 0.70 | JAK2 (0.46) | HTR2CJAK2JAK1TYK2JAK3 | |
| SCHEMBL7600035 | 0.69 | CHRM4 (0.50) | MEN1KMT2ACHRM2 | |
| SCHEMBL616087 | 0.69 | HTR2C (1.00) | HTR2C | |
| SCHEMBL4142576 | 0.68 | MKNK1 (0.42) | HTR2CMEN1KMT2AJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5247052-A | — | — | None | — | — | JP | disclosed |
| EP-1078928-B1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2004-05-12 | — | — | EP | disclosed |
| US-6486171-B2 | USEFUL IN THE TREATMENT OF SOME CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING AS AN ANTIDEPRESSANT; 4-(1-(2-NAPHTHYL)ETHYL)-4- PIPERIDINYL)THIENO(3,2-C)PYRIDINE, FOR EXAMPLE | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | disclosed |
| US-20020161228-A1 | Piperidine compounds | ADIR ET COMPAGNIE | 2002-10-31 | — | — | US | disclosed |
| US-6399616-B1 | 4-(4-(2-(5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL)ETHYL)-1 -PIPERAZINYL)FURO(3,2-C)PYRIDINE; COMBINED SEROTONIN REUPTAKE INHIBITOR AND PARTIAL AGONIST OF 5-HT RECEPTORS; REDUCED LATENCY; DEPRESSION | LES LABORATOIRES SERVIER (FR) | 2002-06-04 | — | — | US | disclosed |
| EP-1078928-A1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | disclosed |
| JP-H05247052-A | 4-(4-PIPERIDINYL)-THIENO-(3,2-C)PYRIDINE DERIVATIVE OF N-ALKYL-GULTALIMIDE | BRISTOL MYERS SQUIBB CO | 1993-09-24 | — | — | JP | disclosed |
| EP-0545421-A1 | 4-(4-piperidinyl-thieno(3,2-c)pyridine derivatives of N-alkylglutarimides as antipsychotic agents | Bristol-Myers Squibb Company (US) | 1993-06-09 | — | — | EP | disclosed |
| US-5137894-A | Psychological disorders | BRISTOL-MYERS SQUIBB COMPANY A CORPORATION OF DELAWARE | 1992-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161228-A1 | Piperidine compounds | OTC, NPPA, AQP4 | HTR2C 1212/4885MEN1 977/4885KMT2A 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.